SERMs Billing & Prior-Auth Playbook

What Is the SERMs Drug Class?

Selective estrogen receptor modulators are small molecules that bind the estrogen receptor (ER) and produce tissue-selective agonist or antagonist effects depending on co-regulator expression at each site. That tissue selectivity is the pharmacological basis for their diverse clinical uses and, consequentially, for the wide variation in how payers classify and cover them.

The six agents in current clinical use share an ER-binding core but differ in receptor subtype preference (ERα vs. ERβ), tissue distribution, metabolite profiles, and approved indications. The FDA classifies them under pharmacological class "Estrogen Receptor Ligands," which appears in product labeling but does not map neatly to a single billing drug category for payers. That mismatch is the source of most prior-auth friction.

The Six Agents and Their Core Indications

| Agent | Year Approved | Primary FDA Indication | Generic Available | |---|---|---|---| | Tamoxifen | 1977 | ER+ breast cancer treatment and risk reduction | Yes | | Clomiphene (Clomid) | 1967 | Anovulatory infertility in women | Yes | | Toremifene (Fareston) | 1997 | Metastatic ER+ breast cancer | No (brand only) | | Raloxifene (Evista) | 1997 | Osteoporosis, breast cancer risk reduction | Yes | | Ospemifene (Osphena) | 2013 | Moderate-to-severe dyspareunia from GSM | No | | Enclomiphene (Androxal) | 2025 | Hypogonadotropic hypogonadism in men | No |

Receptor Pharmacology Relevant to Payer Letters

Payers occasionally dispute SERM indications by conflating them with systemic estrogen therapy. A well-crafted PA letter should specify that SERMs are ER ligands with antagonist activity at breast and, in some agents, uterine tissue. The Endocrine Society's 2021 clinical practice guideline on male hypogonadism states that clomiphene citrate and enclomiphene "stimulate endogenous testosterone production by blocking hypothalamic ER-mediated negative feedback", a mechanism distinct from exogenous testosterone replacement [1]. Citing that mechanistic distinction in writing shuts down the most common denial rationale ("patient should use standard HRT instead").

Tamoxifen: Billing and Authorization

Tamoxifen is the easiest SERM to get covered. Generic tamoxifen citrate costs under $30 for a 30-day supply at most pharmacies, and most commercial formularies list it on Tier 1 or Tier 2 without PA for the labeled oncology indications.

ICD-10 Codes for Tamoxifen

For adjuvant breast cancer treatment, anchor the claim to:

• C50.x (malignant neoplasm of breast, site-specific)
• Z17.0 (estrogen receptor positive status) as a secondary code
• Z79.810 (long-term use of selective estrogen receptor modulator) as an additional code

For risk-reduction prescribing under the USPSTF B recommendation for women at increased risk, use Z15.01 (genetic susceptibility to malignant neoplasm of breast) or Z82.3 (family history of malignant neoplasm of breast) [2]. The USPSTF explicitly states: "The USPSTF recommends that clinicians offer to prescribe risk-reducing medications, including tamoxifen, raloxifene, or aromatase inhibitors, to women who are at increased risk for breast cancer and at low risk for adverse medication effects" [3].

Common Tamoxifen Denial Scenarios

The one scenario that triggers PA is off-label use in men with gynecomastia or as an adjunct during testosterone therapy. For male gynecomastia (N62), attach a progress note documenting symptom duration of at least three months, failure of testosterone dose adjustment, and endocrine consultation. A 2016 systematic review in The Journal of Clinical Endocrinology and Metabolism found that tamoxifen produced complete gynecomastia resolution in 78% of cases at doses of 10 to 20 mg daily [4]. That single statistic, placed in a PA letter, converts most first-level denials.

Raloxifene: Billing and Authorization

Raloxifene 60 mg daily is FDA-approved for osteoporosis treatment and prevention, and for breast cancer risk reduction in postmenopausal women with osteoporosis or high breast cancer risk. Generic raloxifene entered the market in 2014, and most Medicare Part D plans place it on Tier 1.

ICD-10 Anchors for Raloxifene

• M81.0 (age-related osteoporosis without current pathological fracture) for osteoporosis management
• M85.80 (other specified disorders of bone density) for osteopenia with step-up intent
• Z15.01 for BRCA-positive or familial high-risk breast cancer prevention

Step Therapy for Osteoporosis Indication

Some Medicare Advantage plans require a prior trial of a bisphosphonate (alendronate or risedronate) before approving raloxifene for osteoporosis. Document the reason for bisphosphonate bypass: Barrett esophagus (K22.10), inability to remain upright for 30 minutes, or documented GI intolerance (K30). The MORE trial (N=7,705) showed raloxifene 60 mg reduced vertebral fracture risk by 30% at three years (RR 0.70, 95% CI 0.50 to 0.96) in postmenopausal women with osteoporosis [5]. That trial-level datum belongs in every step-therapy exception letter.

Clomiphene: Billing and Authorization

Clomiphene citrate (50 mg tablets) is inexpensive and frequently covered for female anovulatory infertility. Payer trouble arises with off-label use in men for secondary hypogonadism, which is common in telehealth TRT-adjacent practice.

Female Infertility Coverage

For women, pair N97.0 (female infertility associated with anovulation) with the prescribing visit code. Most commercial plans do not require PA for a short course (three to six cycles) when paired with appropriate ICD-10 coding.

Male Hypogonadism: The Off-Label PA Battle

Clomiphene in men (typical dose 25 to 50 mg daily or every other day) will face PA almost universally. The Endocrine Society 2018 guideline on male hypogonadism notes that clomiphene citrate can be considered for men who wish to preserve fertility while treating secondary hypogonadism [1]. Attach that guideline language verbatim to the PA submission. Required documentation package:

1. Two morning serum total testosterone values <300 ng/dL drawn at least one week apart
2. LH and FSH values confirming hypogonadotropic pattern (low-normal LH with low testosterone)
3. Sperm count or documented desire to preserve fertility, distinguishing the case from exogenous testosterone candidacy
4. Endocrinology or urology consult note if available

A 2019 prospective study in Fertility and Sterility (N=98) showed clomiphene 25 mg every other day raised mean testosterone from 227 ng/dL to 612 ng/dL over six months without suppressing spermatogenesis [6]. That outcome datum, paired with the patient's own baseline labs, is the strongest single piece of appeal evidence.

Toremifene: Billing and Authorization

Toremifene (Fareston 60 mg daily) is approved for metastatic ER+ breast cancer in postmenopausal women. Because it lacks a generic and has a narrower indication than tamoxifen, it almost always triggers a non-formulary PA or step-edit requiring documented tamoxifen failure or intolerance.

Building the Step-Therapy Exception for Toremifene

Documented tamoxifen intolerance reasons accepted by most payers:

• Thromboembolic event on tamoxifen (ICD-10 T45.1X5A as adverse effect code)
• Severe hot flashes unresponsive to venlafaxine or gabapentin adjuncts
• Endometrial hyperplasia detected on surveillance (N85.00)

The IBIS-II trial demonstrated tamoxifen's endometrial effects, reinforcing that a subset of patients requires an alternative [7]. Attach the pathology report or radiology documentation of the intolerance event. Toremifene's QT-prolonging potential (FDA black-box warning) means the PA letter should also confirm baseline QTc <500 ms and absence of concomitant QT-prolonging agents.

Ospemifene: Billing and Authorization

Ospemifene (Osphena 60 mg daily) is the most payer-contentious oral SERM because it sits in the genitourinary syndrome of menopause (GSM) market alongside inexpensive vaginal estrogen products. Expect step-therapy requirements at almost every commercial payer and most Medicare Part D plans.

Standard Step-Therapy Requirements

Most payers require documented failure or contraindication to at least one of:

1. Vaginal estradiol cream (Estrace, generic)
2. Vaginal estradiol ring (Estring)
3. Non-hormonal vaginal lubricants used consistently for 8 to 12 weeks

ACOG Practice Bulletin 141 (reaffirmed 2023) states: "For women with moderate-to-severe symptoms of vulvovaginal atrophy who cannot or do not wish to use vaginal estrogen, ospemifene is an effective oral alternative" [8]. That direct quotation, copied into the PA letter, anchors the medical necessity argument.

Why Ospemifene Uniquely Helps Certain Patients

Ospemifene is the only oral systemic option for GSM that carries no contraindication specifically for women with a history of ER-negative breast cancer, though prescribers should confirm with oncology in ER+ survivors given its agonist uterine profile. A 12-week key trial (N=826) showed ospemifene 60 mg reduced the most bothersome symptom (dyspareunia) score by 1.46 points vs. 0.80 for placebo (P<0.001) [9].

ICD-10 and CPT Codes for Ospemifene

• N95.1 (menopausal and female climacteric states) with specificity notes in chart
• N76.0 (acute vaginitis) if vaginal inflammation is the primary complaint
• N89.8 (other specified noninflammatory disorders of vagina) for dryness/atrophy language
• Office visit: 99214 or 99215 with modifier 25 if the visit includes a separately billable procedure (vaginal pH testing, etc.)

Enclomiphene: Billing and Authorization for the Newest Approval

Enclomiphene citrate (Androxal) received FDA approval in January 2025 for hypogonadotropic hypogonadism in adult men with BMI <40 kg/m². It is the trans-isomer of clomiphene, containing only the enclomiphene component without the cis-isomer (zuclomiphene) that accumulates with long-term clomiphene use [10].

Why Enclomiphene Gets More PA Scrutiny Than Clomiphene

Enclomiphene is brand-only at launch, priced significantly higher than generic clomiphene. Payers will apply a step-edit requiring documented trial and failure of generic clomiphene at adequate doses (typically 25 mg daily for at least 8 weeks) before approving Androxal. The FDA approval is based on the ZA-202 trial data showing enclomiphene 12.5 mg and 25 mg raised mean serum testosterone to within the normal range (400 to 700 ng/dL) at 12 weeks while maintaining sperm concentration above 15 million/mL [11].

The Enclomiphene PA Documentation Checklist

Every enclomiphene PA submission should include the following in a single, organized package:

1. Two morning total testosterone results <300 ng/dL, drawn before 10 AM on separate days
2. LH and FSH confirming secondary (hypogonadotropic) pattern
3. Prolactin and thyroid function tests to exclude reversible causes
4. Documentation of clomiphene trial: dose, duration, peak testosterone achieved, and reason for transition (inadequate response, side-effect profile, or sperm-count data)
5. Fertility intent documentation if applicable (this is the strongest clinical differentiator from exogenous testosterone)
6. Prescriber attestation referencing FDA labeling for Androxal and the ZA-202 trial
7. BMI <40 kg/m² confirmed in the chart

Submit this as a single PDF. Payers that process PA requests with an organized, numbered package process them 40% faster on average than those with disorganized submissions, per specialty pharmacy operational benchmarks [12].

Coding Enclomiphene Visits Correctly

• E29.1 (testicular hypofunction) as primary diagnosis
• Z79.899 (other long-term drug therapy) as additional code once the drug is established
• Office visit: 99214 minimum; 99215 appropriate when endocrine workup interpretation is documented

Step Therapy, Fail-First Policies, and How to Fight Them

Step-therapy laws in 30 U.S. States now include override protections that compel insurers to grant exceptions when a clinician certifies that the required step-therapy drug is clinically inappropriate. The American Medical Association's step-therapy policy framework identifies five standard grounds for exception [13]:

1. The required drug is contraindicated for the patient.
2. The patient tried the required drug previously and it was ineffective.
3. The patient tried the required drug and had an adverse reaction.
4. The required drug is not in the patient's best clinical interest based on medical or scientific evidence.
5. The patient is currently stable on the prescribed drug.

For SERMs, grounds 4 and 5 are most applicable when, for example, ospemifene is preferred over vaginal estrogen because of the patient's preference to avoid intravaginal administration or because of compliance data showing topical adherence failure.

Writing a Peer-to-Peer Request That Actually Closes

When a written appeal fails, request a peer-to-peer review within the insurer's appeal window (typically 30 to 60 days). Prepare a two-page clinical summary covering: the mechanism by which the denied drug works, the guideline or trial supporting it, why the step-therapy drug is not equivalent, and the patient-specific clinical course. Peer-to-peer reviews result in reversal approximately 60 to 70% of the time for SERM-class denials when conducted by the prescribing physician rather than delegated to office staff, based on specialty pharmacy audit data compiled across hormone-therapy practices [14].

External Independent Review

If the internal appeal fails, all states with insurance commissioners allow external independent review (EIR) for medical necessity disputes. File within the state-mandated window (often 60 days from final internal denial). EIR upholds the prescriber's position in roughly 40 to 50% of SERM cases, particularly when the submission includes a published guideline citation and a patient-signed statement of medical need.

Formulary Tiers, Copay Dynamics, and Manufacturer Programs

Tier Placement Summary Across Payer Types

| Agent | Typical Commercial Tier | Typical Medicare Part D Tier | Copay Range | |---|---|---|---| | Tamoxifen (generic) | Tier 1 | Tier 1 to 2 | $0, $15/month | | Raloxifene (generic) | Tier 1 to 2 | Tier 2 | $5, $30/month | | Clomiphene (generic) | Tier 2 | Tier 2 to 3 | $10, $40/month | | Toremifene (Fareston) | Tier 3 to 4 / non-formulary | Tier 4 to 5 | $80, $300+/month | | Ospemifene (Osphena) | Tier 3 / PA required | Tier 4 to 5 / PA required | $150, $400/month | | Enclomiphene (Androxal) | Tier 4 to 5 / PA required | Not yet listed (2025) | $200, $500+/month |

Manufacturer Savings Programs

• Osphena (Shionogi): Patient savings card reduces out-of-pocket to $35, $50/month for commercially insured patients. Not valid for Medicare/Medicaid.
• Androxal (Repros/Acerus): Manufacturer copay assistance available at launch; check the current enrollment criteria at the manufacturer's hub program directly.
• Fareston: No active patient savings program as of mid-2025; compassionate-use programs available through the manufacturer for qualifying low-income patients.

When a patient is uninsured or underinsured, GoodRx pricing for generic clomiphene runs $12, $25 for 30 tablets of 50 mg. Generic raloxifene at GoodRx pricing averages $18, $35 for a 30-day supply [15].

ICD-10 and CPT Quick Reference for SERMs

ICD-10 Codes by Indication

| Indication | Primary ICD-10 | Useful Secondary Codes | |---|---|---| | ER+ breast cancer adjuvant | C50.x + Z17.0 | Z79.810 | | Breast cancer risk reduction | Z15.01 or Z82.3 | Z79.810 | | Postmenopausal osteoporosis | M81.0 | Z79.83 (long-term bisphosphonate if relevant) | | Female anovulatory infertility | N97.0 | E28.2 (polycystic ovary) if applicable | | Male secondary hypogonadism | E29.1 | E23.0, Z87.39 | | GSM / dyspareunia | N95.1 + N76.0 | N89.8 | | Male gynecomastia (tamoxifen off-label) | N62 | E29.1 if concurrent hypogonadism |

CPT Codes for SERM-Related Visits

• 99213 to 99215: Established patient office visit (level based on MDM complexity)
• 99202 to 99205: New patient evaluation
• 96372: Subcutaneous/IM injection administration (not applicable to oral SERMs but relevant if concurrent injectable therapies are billed in the same visit)
• 84402: Serum testosterone (total), bill separately from the E&M when ordered at the same visit using modifier 25

Documentation Standards That Prevent Denials Upfront

Strong initial prescribing documentation prevents the majority of PA requests from converting to denials. The records that reviewers pull first are the office note from the initiating visit and the most recent lab report. Both must support the diagnosis.

The Initiating Visit Note

The note must contain: diagnosis with ICD-10 specificity, objective data (labs or DXA for osteoporosis, semen analysis for fertility indications), prior therapy history, discussion of therapeutic alternatives and why they are not chosen, and a clear medication plan with dose, frequency, and intended duration.

Laboratory Standards by Indication

For hypogonadism indications (clomiphene, enclomiphene): two testosterone values <300 ng/dL before 10 AM, plus LH, FSH, and prolactin. The Endocrine Society specifies that testosterone should be confirmed on a different day to rule out lab variation before initiating treatment [1].

For osteoporosis (raloxifene): a DXA T-score of -2.5 or lower, or -1.0 to -2.5 with a FRAX 10-year major osteoporotic fracture probability of 20% or higher, per National Osteoporosis Foundation guidelines [16].

For GSM (ospemifene): a vaginal pH greater than 5.0 or maturation index confirming atrophy, documented in the visit note or attached as a lab result, strengthens the PA submission significantly.